ku, they will in all cases keep extending bavituximab and no company approaching it is impossible since AstraZeneca already did.
They will in all cases do SMALL clinical trials and let AZ deliver the I-O (Durvalumab)while other trials are within their already paid for agreements with memorial Sloan Kettering and NCCN and UTSW.
But that is INSUFFICIENT IMO and depending on the Avid fast growth they will for sure use some other means of funding (ATM, new special offering, ???).
So a deal that either covers the COMPLETE clinical trial cost (not just Durvalumab), some temporary EXCLUSIVE Bavituximab usage in clinical trials for cash, a big GOV order over multiple years or a partnership with up-front cash or of course a surprise Bavituximab approval (BTK or BLA negotiated under the FDA's Fast Track possibilities asking approval under conditions, etc) are all possibilities.
My personal preference is know, all deals with NO PERMANENT encumbering of the pipelines (IP will not be encumbered IMO) will do. I prefer a slightly slower move (1 Year) then a fast poor panic deal because there is no reason for panic.
Market Data 
Markets 
AI
